iPS-NSC cells vs XS-411

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: dopaminergic neuron replacement · full Parkinson's Disease pipeline

iPS-NSC cells

Developed by Allife Medical Science and Technology

Phase 1 in Parkinson's Diseasecell therapy
Weak signal

NCT03815071 · Phase 1 · status unknown

This is a small, single-arm, unblinded study of 10 participants with no control group, designed to check safety rather than test efficacy against a comparator, and results have not yet been posted.

No aligned efficacy figure on record for this race.

XS-411

Developed by XellSmart Bio-Pharmaceutical (Suzhou)

Phase 1/2 in Parkinson's Diseasecell therapy
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: July 2027 · NCT07080775 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointiPS-NSC cellsXS-411
OFF time, change—Not reported—Not reported
ON time without troublesome dyskinesia, change—Not reported—Not reported
UPDRS Part III, change—Not reported—Not reported
MDS-UPDRS Part II, change—Not reported—Not reported

OFF time, change

iPS-NSC cells
—Not reported
XS-411
—Not reported

ON time without troublesome dyskinesia, change

iPS-NSC cells
—Not reported
XS-411
—Not reported

UPDRS Part III, change

iPS-NSC cells
—Not reported
XS-411
—Not reported

MDS-UPDRS Part II, change

iPS-NSC cells
—Not reported
XS-411
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

iPS-NSC cells: no structured comparison results are available for Parkinson's Disease.

XS-411: no structured comparison results are available for Parkinson's Disease.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: iPS-NSC cells's landscape · XS-411's landscape